Sign In
Buy ZEAL
$17.59
+0 (+0%)
At Close: Jan 27, 2023
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
01:00am, Monday, 12'th May 2025
Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (C
Zealand Pharma announces closing of collaboration and license agreement with Roche
12:25am, Friday, 09'th May 2025
Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Z
Zealand Pharma Announces Financial Results for the First Three Months of 2025
01:00am, Thursday, 08'th May 2025
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capa
Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUP
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
09:00am, Wednesday, 23'rd Apr 2025
Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as
Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenh
Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, Apr
Resolutions from Zealand Pharma's Annual General Meeting 2025
01:20pm, Thursday, 27'th Mar 2025
Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
12:00pm, Tuesday, 25'th Mar 2025
Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
12:00pm, Thursday, 20'th Mar 2025
Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand
Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Ph
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people wit
Correction: Zealand Pharma Announces Financial Results for the Full Year 2024
04:08am, Thursday, 20'th Feb 2025
Company announcement – No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format.
Zealand Pharma Announces Financial Results for the Full Year 2024
01:00am, Thursday, 20'th Feb 2025
Company announcement – No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipe
Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenha
